Key statistics
On Friday, Travere Therapeutics Inc (17R:BER) closed at 13.40, -0.74% below its 52-week high of 13.50, set on Sep 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.50 |
---|---|
High | 13.50 |
Low | 13.20 |
Bid | 13.40 |
Offer | 14.40 |
Previous close | 13.50 |
Average volume | 232.50 |
---|---|
Shares outstanding | 76.49m |
Free float | 75.84m |
P/E (TTM) | -- |
Market cap | 1.16bn USD |
EPS (TTM) | -4.99 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 19:30 BST.
More ▼
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
- Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
- Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
- Travere Therapeutics to Present at Upcoming Investor Conferences
- Travere Therapeutics Reports Second Quarter 2024 Financial Results
- Travere Therapeutics to Report Second Quarter 2024 Financial Results
- Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
- Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
- Travere Therapeutics Reports First Quarter 2024 Financial Results
More ▼